ClinicalTrials.gg
CompletedNCT01772316Updated Nov 7, 2016Results posted

A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 12 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-07.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
79th of 110
47 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
71st of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 71st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label, single arm, long-term extension study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in participants with moderate to severe rheumatoid arthritis who have completed the 97-week WA22762 or the 96-week NA25220 core study. Participants will receive RoActemra/Actemra 162 milligram (mg) subcutaneously weekly (for participants entering from WA22762) or every two weeks (for participants entering from NA25220) for 96 weeks, with telephone call follow-up visits at Weeks 100 and 104.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants, >/= 18 years of age
  • Participants who have completed the 97-week WA22762 or 96-week NA25220 core study on subcutaneous or intravenous RoActemra/Actemra and based on the investigator's judgment may continue to benefit from RoActemra/Actemra treatment in this study investigating the subcutaneous formulation
  • Oral and non-steroidal anti-inflammatory drugs (NSAIDS) up to the maximum recommended dose are permitted if on a stable dose regimen for >/= 4 weeks prior to baseline
  • Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed
  • Receiving treatment on an outpatient basis
  • Females of and males with female partners of childbearing potential must agree to use reliable means of

Exclusion criteria

Exclusion Criteria:

  • Participants who have prematurely withdrawn from the WA22762 or NA25220 core studies for any reason
  • Previous treatment with any cell-depleting therapies, including agents or approved therapies
  • History of severe allergic or anaphylactic reactions to human, humanized or mural monoclonal antibodies
  • Evidence of serious uncontrolled concomitant disease
  • Current liver disease as determined by the principal investigator
  • History of diverticulitis, diverticulosis requiring antibiotic treatment or chronic ulcerative lower gastrointestinal (GI) disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations
  • Known active current or history of recurrent infections
  • Any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
  • Active tuberculosis requiring treatment within the previous 3 years
  • Primary or secondary immunodeficiency (history of or currently active)
  • Pregnant or breast feeding women
  • Body weight > 150 kilogram (kg)
  • Inadequate renal, hepatic or hematologic function
  • Positive for or
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Tocilizumab Subcutaneous (SC)

    Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.

    Drug: tocilizumab

Interventions

  • 162 mg subcutaneously weekly or every two weeks, 96 weeks

    Also known as: Roactemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a clinical investigation participant that was administered study drug, regardless of causal attribution.

    Time frame: Baseline up to follow-up (Week 104)

  2. Percentage of Participants Withdrawn From the Study Due to Lack of Therapeutic Response

    Time frame: Baseline up to follow-up (Week 104)

  3. Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 48

    The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis. The index included swollen joint count (SJC), tender joint count (TJC), acute phase response (ESR or high sensitivity C-reactive protein \[hsCRP\]) and general health status (GH). For this study, ESR was used to calculate DAS28 score. The index was calculated using the following formula: DAS28 = (0.56 × √\[TJC 28\]) + (0.28 × √\[SJC 28\]) + (0.7 × ln\[ESR\]) + (0.014 × GH). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Change in DAS28ESR=DAS28-ESR at Week 48 - DAS28-ESR at Baseline.

    Time frame: Baseline, Week 48

  4. Change From Baseline in DAS28-ESR at Week 96

    The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis. The index included SJC, TJC, acute phase response (ESR or high sensitivity C-reactive protein \[hsCRP\]) and general health status. For this study, ESR was used to calculate DAS28 score. The index was calculated using the following formula: DAS28 = (0.56 × √\[TJC28\]) + (0.28 × √\[SJC28\]) + (0.7 × ln\[ESR\]) + (0.014 × GH). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Change in DAS28ESR=DAS28-ESR at Week 96 - DAS28-ESR at Baseline.

    Time frame: Baseline, Week 96

  5. Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 48

    The SDAI was the numerical sum of five outcome parameter: SJC and TJC, Patient Global Assessment of Disease Activity (PGA) and Investigator Global Assessment of Disease Activity (IGA), and level of hsCRP. The index was calculated using the following formula SDAI = TJC28 + SJC28 + PGA + IGA + CRP. Change in SDAI = SDAI at Week 48 - SDAI at Baseline. SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. Here, n signifies the number of subjects evaluable at the specified time points.

    Time frame: Baseline, Week 48

  6. Change From Baseline in SDAI at Week 96

    The SDAI was the numerical sum of five outcome parameter: SJC and TJC, PGA and IGA, and level of hsCRP. The index was calculated using the following formula SDAI = TJC28 + SJC28 + PGA + IGA + CRP. Change in SDAI = SDAI at Week 96 - SDAI at Baseline. SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

    Time frame: Baseline, Week 96

  7. Change From Baseline in Total Tender Joint Count (TJC) at Week 48

    An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A smaller number indicated improvement. Here, 'n' represents the number of participants with a measure at specified time point.

    Time frame: Baseline, Week 48

  8. Change From Baseline in Total TJC at Week 96

    An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A smaller number indicated improvement.

    Time frame: Baseline, Week 96

  9. Change From Baseline in Swollen Joint Count (SJC) at Week 48

    An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A negative number indicated improvement.

    Time frame: Baseline, Week 48

  10. Change From Baseline in SJC at Week 96

    An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. Change in SJC = SJC at Week 96 - SJC at Baseline. A negative number indicated improvement.

    Time frame: Baseline, Week 96

Secondary outcomes

  1. Percentage of Participants With Remission (DAS28 <2.6 or SDAI </=3.3) at Weeks 48 and 96

    Time frame: Week 48, Week 96

  2. Percentage of Participants With Disease-Modifying Antirheumatic Drugs (DMARDs)/Corticosteroid Dose Reductions and/or Discontinuation

    Time frame: Randomization of first participant to clinical cutoff date (19MAY2015) (approximately 29 months)

  3. Patient Global Visual Analog Score (VAS) at Specified Time Points

    This assessment represents the patient's overall assessment of their current disease activity on a 100 millimeter (mm) horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). Scores ranged from 0 to 100 with a higher score indicating more disease activity. A negative change score indicated less disease activity.

    Time frame: Baseline, Week 48, Week 96

  4. Patient Pain VAS Score at Specified Time Points

    This assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain". Scores ranged from 0 to 100 with a higher score indicating more pain. A negative change score indicated less pain.

    Time frame: Baseline, Week 48, Week 96

  5. Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Specified Time Points

    The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Minimum score was 0, maximum score was 3. A smaller score indicated improvement.

    Time frame: Baseline, Week 48, Week 96

07

Results

Posted Aug 29, 2016

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab Subcutaneous (SC)
Started47
Completed40
Not completed7
Withdrew: Serious adverse event1
Withdrew: Inform consent withdrawn1
Withdrew: Withdrawn by sponsor decision5

Outcome measures

PrimaryPercentage of Participants With an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a clinical investigation participant that was administered study drug, regardless of causal attribution.

Time frame:
Baseline up to follow-up (Week 104)
Reported as:
Number · percentage of participants
Percentage of Participants With an Adverse Event (AE)
percentage of participantsTocilizumab Subcutaneous (SC)
Percentage of Participants With an Adverse Event (AE)83
PrimaryPercentage of Participants Withdrawn From the Study Due to Lack of Therapeutic Response
Time frame:
Baseline up to follow-up (Week 104)
Reported as:
Number · percentage of participants
Percentage of Participants Withdrawn From the Study Due to Lack of Therapeutic Response
percentage of participantsTocilizumab Subcutaneous (SC)
Percentage of Participants Withdrawn From the Study Due to Lack of Therapeutic Response0
PrimaryChange From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 48

The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis. The index included swollen joint count (SJC), tender joint count (TJC), acute phase response (ESR or high sensitivity C-reactive protein \[hsCRP\]) and general health status (GH). For this study, ESR was used to calculate DAS28 score. The index was calculated using the following formula: DAS28 = (0.56 × √\[TJC 28\]) + (0.28 × √\[SJC 28\]) + (0.7 × ln\[ESR\]) + (0.014 × GH). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Change in DAS28ESR=DAS28-ESR at Week 48 - DAS28-ESR at Baseline.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 48
units on a scaleTocilizumab Subcutaneous (SC)
Baseline2.9 ± 1.4
Change at Week 48-0.832 ± 0.292
PrimaryChange From Baseline in DAS28-ESR at Week 96

The DAS28 is a combined index for measuring disease activity in rheumatoid arthritis. The index included SJC, TJC, acute phase response (ESR or high sensitivity C-reactive protein \[hsCRP\]) and general health status. For this study, ESR was used to calculate DAS28 score. The index was calculated using the following formula: DAS28 = (0.56 × √\[TJC28\]) + (0.28 × √\[SJC28\]) + (0.7 × ln\[ESR\]) + (0.014 × GH). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Change in DAS28ESR=DAS28-ESR at Week 96 - DAS28-ESR at Baseline.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 96
units on a scaleTocilizumab Subcutaneous (SC)
Change From Baseline in DAS28-ESR at Week 96-0.804 ± 0.230
PrimaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Week 48

The SDAI was the numerical sum of five outcome parameter: SJC and TJC, Patient Global Assessment of Disease Activity (PGA) and Investigator Global Assessment of Disease Activity (IGA), and level of hsCRP. The index was calculated using the following formula SDAI = TJC28 + SJC28 + PGA + IGA + CRP. Change in SDAI = SDAI at Week 48 - SDAI at Baseline. SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity. Here, n signifies the number of subjects evaluable at the specified time points.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 48
units on a scaleTocilizumab Subcutaneous (SC)
Baseline12.2 ± 10.7
Change at Week 48-7.572 ± 2.115
PrimaryChange From Baseline in SDAI at Week 96

The SDAI was the numerical sum of five outcome parameter: SJC and TJC, PGA and IGA, and level of hsCRP. The index was calculated using the following formula SDAI = TJC28 + SJC28 + PGA + IGA + CRP. Change in SDAI = SDAI at Week 96 - SDAI at Baseline. SDAI total score = 0-86. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in SDAI at Week 96
units on a scaleTocilizumab Subcutaneous (SC)
Change From Baseline in SDAI at Week 96-6.599 ± 2.210
PrimaryChange From Baseline in Total Tender Joint Count (TJC) at Week 48

An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A smaller number indicated improvement. Here, 'n' represents the number of participants with a measure at specified time point.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in Total Tender Joint Count (TJC) at Week 48
units on a scaleTocilizumab Subcutaneous (SC)
Baseline2.5 ± 4.1
Change at Week 481.3 ± 2.0
PrimaryChange From Baseline in Total TJC at Week 96

An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A smaller number indicated improvement.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in Total TJC at Week 96
units on a scaleTocilizumab Subcutaneous (SC)
Change From Baseline in Total TJC at Week 961.5 ± 3.6
PrimaryChange From Baseline in Swollen Joint Count (SJC) at Week 48

An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. A negative number indicated improvement.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in Swollen Joint Count (SJC) at Week 48
units on a scaleTocilizumab Subcutaneous (SC)
Baseline1.8 ± 3.4
Change at Week 48-1.531 ± 0.587
PrimaryChange From Baseline in SJC at Week 96

An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as tender/not tender and swollen/not swollen by pressure and joint manipulation on physical examination. Change in SJC = SJC at Week 96 - SJC at Baseline. A negative number indicated improvement.

Time frame:
Baseline, Week 96
Reported as:
Mean · units on a scale
Change From Baseline in SJC at Week 96
units on a scaleTocilizumab Subcutaneous (SC)
Change From Baseline in SJC at Week 96-1.188 ± 0.543
SecondaryPercentage of Participants With Remission (DAS28 <2.6 or SDAI </=3.3) at Weeks 48 and 96
Time frame:
Week 48, Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Remission (DAS28 <2.6 or SDAI </=3.3) at Weeks 48 and 96
percentage of participantsTocilizumab Subcutaneous (SC)
DAS <2.6 at Week 4871.9
DAS <2.6 at Week 9662.5
SDAI </=3.3 at Week 4828.6
SDAI </=3.3 at Week 9629.6
SecondaryPercentage of Participants With Disease-Modifying Antirheumatic Drugs (DMARDs)/Corticosteroid Dose Reductions and/or Discontinuation
Time frame:
Randomization of first participant to clinical cutoff date (19MAY2015) (approximately 29 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease-Modifying Antirheumatic Drugs (DMARDs)/Corticosteroid Dose Reductions and/or Discontinuation
percentage of participantsTocilizumab Subcutaneous (SC)
Percentage of Participants With Disease-Modifying Antirheumatic Drugs (DMARDs)/Corticosteroid Dose Reductions and/or Discontinuation38.2
SecondaryPatient Global Visual Analog Score (VAS) at Specified Time Points

This assessment represents the patient's overall assessment of their current disease activity on a 100 millimeter (mm) horizontal VAS. The extreme left end of the line should be described as "no disease activity" (symptom free and no arthritis symptoms) and the extreme right end as "maximum disease activity" (maximum arthritis disease activity). Scores ranged from 0 to 100 with a higher score indicating more disease activity. A negative change score indicated less disease activity.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · units on a scale
Patient Global Visual Analog Score (VAS) at Specified Time Points
units on a scaleTocilizumab Subcutaneous (SC)
Baseline (n=34)30.8 ± 21.8
Week 48 (n=33)30.0 ± 22.6
Week 96 (n=33)26.0 ± 21.8
SecondaryPatient Pain VAS Score at Specified Time Points

This assessment represents the patient's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line should be described as "no pain" and the extreme right end as "unbearable pain". Scores ranged from 0 to 100 with a higher score indicating more pain. A negative change score indicated less pain.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · units on a scale
Patient Pain VAS Score at Specified Time Points
units on a scaleTocilizumab Subcutaneous (SC)
Baseline (n=34)32.4 ± 21.8
Week 48 (n=33)29.8 ± 21.3
Week 96 (n=33)27.0 ± 22.2
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI) Score at Specified Time Points

The HAQ-DI is a questionnaire specific for rheumatoid arthritis and consists of 20 questions referring to 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Minimum score was 0, maximum score was 3. A smaller score indicated improvement.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · units on a scale
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Specified Time Points
units on a scaleTocilizumab Subcutaneous (SC)
Baseline (n=34)0.8 ± 0.6
Week 48 (n=33)0.7 ± 0.5
Week 96 (n=33)0.8 ± 0.7

Adverse events

Collected over Baseline up to follow-up (Week 104). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Subcutaneous (SC)—3/47 (6.4%)39/47 (83%)
Most frequent serious events
Most frequent serious events
EventTocilizumab Subcutaneous (SC)
Renal colicRenal and urinary disorders1/47
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/47
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/47
Most frequent other events
Most frequent other events
EventTocilizumab Subcutaneous (SC)
Respiratory tract infectionInfections and infestations13/47
Back painMusculoskeletal and connective tissue disorders7/47
Urinary tract infectionInfections and infestations5/47
NeutropeniaBlood and lymphatic system disorders3/47
GastroenteritisInfections and infestations3/47
WoundInjury, poisoning and procedural complications3/47
Pain in extremityMusculoskeletal and connective tissue disorders3/47
CoughRespiratory, thoracic and mediastinal disorders3/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tocilizumab Subcutaneous (SC)
Mean59.3 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab Subcutaneous (SC)
Female40
Male7
08

Study locations

12 sites
  • Mérida, Badajoz 06800, Spain
  • Santander, Cantabria 39008, Spain
  • A Coruña, La Coruña 15006, Spain
  • Santiago de Compostela, La Coruña 15706, Spain
  • Madrid, Madrid 28007, Spain
  • Madrid, Madrid 28046, Spain
  • Málaga, Malaga 29009, Spain
  • Seville, Sevilla 41009, Spain
  • San Cristóbal de La Laguna, Tenerife 38320, Spain
  • Valenica, Valencia 46009, Spain
  • Barakaldo, Vizcaya 48903, Spain
  • Bilbao, Vizcaya 48013, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2013
First posted
Jan 21, 2013
Start
Dec 2012
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Aug 29, 2016
Last update
Nov 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01772316
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Dec 2012
Primary completion
May 2015
Completion
May 2015
Results posted
Aug 29, 2016
Last update
Nov 7, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion